Objectives: An effective vaccine against cholera has been used for public health purposes in Vietnam since the 1990s. This vaccine was reformulated to meet WHO requirements. We assessed the safety and immunogenicity of the reformulated bivalent (Vibrio cholerae 01 and 0139) killed whole cell oral vaccine in a cholera endemic area in Kolkata, India.
Design: Double-blind, randomized, placebo controlled trial.
Setting: The trial was conducted in the clinical trial ward of the Infectious Diseases Hospital in Kolkata, India.
Participants: The participants were 101 healthy adults (males and non-pregnant females) aged 18-40 years and 100 healthy children (males and non-pregnant females) aged 1-17 years.
Interventions: Participants were randomized to receive either the bivalent killed whole cell oral cholera vaccine or placebo (killed oral Escherichia coli K12).
Outcome Measures: For safety: proportion of subjects with adverse events during the duration of study participation. For immunogenicity: Proportion of subjects who had a > or = 4-fold rise in serum vibriocidal antibody titers 14 days after the second dose of vaccine or placebo.
Results: Adverse reactions were observed with similar frequency among vaccine and placebo recipients in both age groups. Among adults 4% of vaccine and 8% of placebo recipients and among children 4% of vaccine and 2% of placebo recipients had at least one adverse event within 28 days of the first dose of the vaccine. Following immunization, 53% of adult and 80% of children vaccinees showed a > or = 4 fold rise in serum V. cholerae O1 vibriocidal antibody titers. A less pronounced response to V. cholerae O139 vibriocidal antibody titers post-immunization was noted among vaccinees.
Conclusions: We found the vaccine to be safe and immunogenic in a cholera-endemic area in India.
Trial Registration: ClinicalTrials.gov NCT00119197.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2396289 | PMC |
| http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0002323 | PLOS |
Publication Analysis
Top Keywords
Similar Publications
Background: ALZ-101 is a vaccine comprised of stabilised oligomeric Aβ42 that stimulates a humoral immune response primarily targeting a toxic, low-abundant oligomeric form of Aβ. Part A of a clinical Phase 1b trial (ALZ-C-001; NCT05328115) was recently concluded with the objectives to assess the safety, tolerability and immunogenicity of ALZ-101 in subjects with mild AD or MCI due to AD.
Methods: Participants were randomised to receive placebo (n = 6), 125 µg (n = 10) or 250 µg (n = 10) doses of ALZ-101 at weeks 0, 4, 8, and 16.
Randomized controlled trial comparing the immunogenicity of experimental Salmonella Dublin siderophore receptor vaccines in calves.
Am J Vet Res
January 2025
Department of Veterinary Diagnostic and Production Animal Medicine, College of Veterinary Medicine, Iowa State University, Ames, IA.
Objective: To describe immune responses following administration of experimental Salmonella Dublin siderophore receptor protein (SRP) vaccines in Holstein heifer calves with adequate passive antibody transfer.
Methods: Calves were randomly assigned to receive placebo, vaccination with S Dublin SRP in adjuvant A, or vaccination with S Dublin SRP in adjuvant B at 7 ± 3 days of age and 3 weeks later. Before each vaccination, 4 and 8 days after the second vaccination (postvaccination), and 61 to 91 days postvaccination, S Dublin antibody titers were measured.
Evaluation of Safety, Immunogenicity and Cross-Reactive Immunity of OVX836, a Nucleoprotein-Based Universal Influenza Vaccine, in Older Adults.
Vaccines (Basel)
December 2024
Osivax, 70 Rue Saint-Jean-de-Dieu, 69007 Lyon, France.
In a Phase 2a, double-blind, placebo-controlled study including healthy participants aged 18-55 years, OVX836, a nucleoprotein (NP)-based candidate vaccine, previously showed a good safety profile, a robust immune response (both humoral and cellular) and a preliminary signal of protection (VE = 84%) against PCR-confirmed symptomatic influenza after a single intramuscular dose of 180 µg, 300 µg or 480 µg. : Using the same methodology, we confirmed the good safety and strong immunogenicity of OVX836 at the same doses in older adults (≥65 years), a key target population for influenza vaccination. : Significant humoral (anti-NP IgG) and cellular (interferon gamma (IFNγ) spot-forming cells per million peripheral blood mononuclear cells and specific CD4 IFNγ T-cells) immune responses were observed at the three dose levels, without clear dose-response relationship.
View Article and Find Full Text PDFThe Safety and Efficacy of New DIVA Inactivated Vaccines Against Lumpy Skin Disease in Calves.
Vaccines (Basel)
November 2024
Istituto Zooprofilattico Sperimentale dell'Abruzzo e del Molise "G. Caporale", 64100 Teramo, Italy.
Lumpy skin disease virus ( family- genus) is the aetiological agent of LSD, a disease primarily transmitted by hematophagous biting, affecting principally cattle. Currently, only live attenuated vaccines are commercially available, but their use is limited to endemic areas. There is a need for safer vaccines, especially in LSD-free countries.
View Article and Find Full Text PDFImmunogenicity, Safety, and Reactogenicity of Concomitant Administration of the Novavax Vaccine against Omicron XBB.1.5 (NVX-CoV2601) and a 20-valent Pneumococcal Conjugate Vaccine in Adults Aged ≥60 Years: A Randomised, Double-blind, Placebo-controlled, Non-inferiority Trial.
J Infect
January 2025
Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria. Electronic address:
Objectives: There is conflicting evidence as to whether the combined administration of two vaccines can lead to poorer immunogenicity and reactogenicity. The co-administration of the Omicron-adapted COVID-19 vaccine from Novavax (NVX-CoV2601) and a 20-valent pneumococcal conjugate vaccine (PCV20) has not been previously investigated.
Methods: In this randomised, double-blind, placebo-controlled, non-inferiority trial, immunocompetent participants aged ≥60 years were randomised in a 1:1:1:1 ratio to four groups: NVX-CoV2601 plus PCV20 (combination group); NVX-CoV2601 plus placebo (NVX-only group); PCV20 plus placebo (PCV20-only group); or placebo plus placebo (placebo group).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!